Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer-Reference-Cited by-同舟云学术

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

Published:2019-07-22 Issue:9 Volume:10 Page:1798-1804
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Komiya Kazutoshi¹^ORCID,Nakamura Tomomi¹,Abe Tomonori¹,Ogusu Shinsuke¹,Nakashima Chiho¹,Takahashi Koichiro¹,Kimura Shinya¹,Sueoka‐Aragane Naoko¹

Affiliation:

1. Division of Hematology, Respiratory Medicine and Oncology, Faculty of MedicineSaga University Saga Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13149

Reference24 articles.

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

5. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

2. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07

3. Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-06-26

4. Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report;Current Problems in Cancer: Case Reports;2024-06

5. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis;Frontiers in Oncology;2024-05-08